Participants ( plasma HIV-RNA > 1000 log10 copies per mL , CD4 T-cell count 50-500 cells per L ) were randomly assigned by a computer-generated sequence with a blocking factor of four ( stratified by clinical site and by screening viral load ) to receive tenofovir plus emtricitabine with either a reduced daily dose ( 400 mg ) or a standard dose ( 600 mg ) of efavirenz .